Table 2.
Characteristics of included studies
| Study | PI | Study design | Study population | Target sample size | Length of follow-up (months) | Recruited sample size | Retention (%) excluding mortality unless indicated | Study duration |
|---|---|---|---|---|---|---|---|---|
| Longitudinal Study of the Ocular Complications of AIDS (LSOCA) [24, 25] | Thorne | Prospective Cohort | Patients with acquired immunodeficiency syndrome | 2800 | 60 | 2200 | 93% | 1998–2012 |
| Improving Care of Acute Lung Injury Patients (ICAP) [13, 18] | Pronovost/Needham | Prospective Cohort | Patients with acute lung injury/acute respiratory distress syndrome | 520 | 60 | 520 | 94% | 2004–12 |
| Longitudinal Study of Alzheimer’s Disease and Other Memory Disorders (LSADOMD) part of the National Institute on Aging’s Alzheimer’s Disease Research Centers [26] | Lyketsos | Prospective Cohort | People ≥60y with or without memory problems | 500 | Until death | 500 | ≥80%c | 1985-ongoing |
| Enroll Huntington’s Disease (Enroll-HD) [27] | Ross | Prospective Cohort | Patients with Huntington’s Disease and their family members | 2285 | Until death | 793 | ≥80%c | 2012-ongoing |
| Alzheimer’s Disease Anti-inflammatory Prevention Trial (ADAPT) [12] | Lyketsos | RCT | Healthy elderly individual with a family history of Alzheimer’s Disease | 2625 | Average 20 | 2528 | 84%b | 2000–04 |
| Mr. Bean - The associations between HIV, early-stage kidney disease, and cardiovascular disease [28] | Lucas | Prospective Cohort | People living with and without HIV | 300 | 36 | 292 | 83%b | 2010-ongoing |
| Active Surveillance of Prostate Cancera [16] | Carter | Prospective Cohort | Men with suspected lower grade prostate cancer | 10,000 | 216 | 1369 | 98% | 2005-ongoing |
| Action for Health in Diabetes Continuation (Look AHEAD-C) [29] | Clark | RCT | People living with chronic renal insufficiency | 310 | 28 | 320 | 93% | 2010-ongoing |
| Cohort Study to Determine Markers for the Development of Severe Vascular Events in Sclerodermad | Hummers | Prospective Cohort | People living with scleroderma | 300 | 72 | 300 | 99% | 2006-ongoing |
| Longitudinal Study of various types of Fuch’s corneal dystrophy [30] | Gottsch | Prospective Cohort | Fuch’s Corneal Dystrophy patients and family members | Not provided | Until death | Not provided | ≥80%c | 2005-ongoing |
| Community Aging in Place Advancing Better Living for Elders (CAPABLE) [11] | Szanton | RCT | Older adults aging in place | 300 | 12 | 205 | 85% | 2012-ongoing |
| Chronic Renal Insufficiency Cohort (CRIC) [20] | Appel | Prospective Cohort | People living with chronic renal insufficiency | 275 | 24 | 276 | 99% | 2002-ongoing |
| Study of HIV Infection in the Etiology of Lung Disease (SHIELD) [31] | Kirk | Prospective Cohort | General adult population | 4000 | >60 | 2200 | ≥80%c | 2009-ongoing |
| Early Detection and Predicting Recurrence in Non Small Cell Lung Cancera [32] | Brock | Prospective Cohort | Non-small cell lung cancer patients | 500 | >60 | 581 | ≥80%c | 2007-ongoing |
| Early Markers of Alzheimer’s Disease in Selected BLSA Participants: Structural and Functional Brain Changes [33] | Moghekar | Prospective Cohort | Older adults participating in the Baltimore Longitudinal Study of Aging | - | Until death | 634 | 99%b | 2010-ongoing |
| SHARE Project - Effectiveness of a Housing Intervention for Battered Women [15] | Glass | Quasi-experimental (pre/post) | Victims of intimate partner violence | 300 | 18 | 278 | 94% | 2006–2010 |
| ARDS Network Long Term Outcome Study (ALTOS) [17, 19] | Needham | RCT | Patients with acute respiratory distress syndrome | 922 | 12 | 922 | 94% | 2008–2014 |
| SPIROMICS - Sub-populations and intermediate outcome measures in COPD study [34] | Hansel | Prospective Cohort | Chronic obstructive pulmonary disease patients | 255 | 36 | 253 | 81%b | 2010-ongoing |
| Internet Resource for Intervention and Safety (IRIS) [21] | Glass | RCT | Victims of intimate partner violence | 720 | 12 | 720 | 93%b | 2011–2014 |
Abbreviations: RCT randomized control trial
aStudy embedded in clinic visits
bIncludes mortality in denominator
cActual retention rate could not be provided. At least 80% retention rate per response to screening questionnaire
dNo citation available